Life Technologies Stockholders to Meeting on Thermo Fisher Scientific Acquisition
Life Technologies Corporation has filed a definitive proxy statement with the US Securities and Exchange Commission regarding Thermo Fisher Scientific Inc.
Life Technologies Corporation, a leading life sciences company, has filed a definitive proxy statement with the US Securities and Exchange Commission regarding Thermo Fisher Scientific Inc.'s pending acquisition of the Company and has set the Wednesday, August 21, 2013, at 8:00 a.m. Pacific Time. for a special meeting of stockholders to approve the transaction.
All stockholders of record of Life Technologies' common stock as of the close of business on July 18, 2013, will be entitled to vote their shares either in person or by proxy. Under the terms of the merger agreement, each outstanding share of Life Technologies common stock would be converted into the right to receive $76.00 in cash, subject to potential increase in certain circumstances if the merger does not close by January 14, 2014, as described in the definitive proxy statement.
The Life Technologies' board of directors unanimously recommended that stockholders vote "FOR" the adoption of the merger agreement. The transaction, which is expected to be completed early in 2014, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including adoption of the merger agreement by Life Technologies' stockholders at the special meeting.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
